1. S31 Dupilumab reduces severe exacerbations across baseline disease characteristics in patients with elevated baseline type 2 biomarkers: the LIBERTY ASTHMA QUEST study. (12th November 2019) Authors: Busse, WW; Muñoz, X; Casale, TB; Paggiaro, P; Castro, M; Tohda, Y; Rice, MS; Deniz, Y; Rowe, P; Amin, N; Teper, A Journal: Thorax Issue: Volume 74(2019)Supplement 2 Page Start: A21 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P44 Dupilumab reduces exacerbations and improves lung function in uncontrolled, moderate-to-severe asthma patients regardless of prior exacerbation history in the phase 3 LIBERTY ASTHMA QUEST study. (December 2018) Authors: Pavord, I; Ford, LB; Corren, J; Kuna, P; Dong, Q; Staudinger, H; Maroni, J; Rowe, P; Rout, R; Amin, N; Akinlade, B; Graham, NMH; Teper, A Journal: Thorax Issue: Volume 73(2018)Supplement 4 Page Start: A121 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. S78 Dupilumab reduces risk of severe exacerbations and improves FEV1 regardless of baseline disease severity in patients with uncontrolled, moderate-to-severe asthma: data from the phase 3 LIBERTY ASTHMA QUEST study. (December 2018) Authors: Pavord, I; Papi, A; Wenzel, S; Park, HS; Rice, M; Staudinger, H; Maroni, J; Rowe, P; Rout, R; Amin, N; Akinlade, B; Graham, NMH; Teper, A Journal: Thorax Issue: Volume 73(2018)Supplement 4 Page Start: A48 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. S49 Dupilumab improves lung function across baseline disease characteristics in patients with evidence of type 2 inflammation at baseline: the LIBERTY ASTHMA QUEST study. (12th November 2019) Authors: Paggiaro, P; Castro, M; Canonica, WG; Douglass, JA; Tohda, Y; Rice, MS; Deniz, Y; Rowe, P; Amin, N; Teper, A Journal: Thorax Issue: Volume 74(2019)Supplement 2 Page Start: A33 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P58: DUPILUMAB EFFICACY AND EFFECT ON ASTHMA CONTROL IN PATIENTS WITH UNCONTROLLED PERSISTENT ASTHMA AND COMORBID CHRONIC RHINOSINUSITIS WITH OR WITHOUT NASAL POLYPS. (7th September 2017) Authors: Katelaris, CH; Maspero, JF; Jayawardena, S; Rowe, P; Maroni, J; Pirozzi, G; Amin, N; NMH, Graham; Mannent, L; Teper, A Journal: Internal medicine journal Issue: Volume 47(2017)Supplement 5 Page Start: 22 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Safety, tolerability, and pharmacokinetics (PK) of treprostinil palmitil inhalation powder (TPIP): a phase 1, randomised, double-blind, single- and multiple-dose study. (14th October 2021) Authors: Ismat, F A; Usansky, H; Dhar Murthy, S; Zou, J; Teper, A Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P58: DUPILUMAB EFFICACY AND EFFECT ON ASTHMA CONTROL IN PATIENTS WITH UNCONTROLLED PERSISTENT ASTHMA AND COMORBID CHRONIC RHINOSINUSITIS WITH OR WITHOUT NASAL POLYPS. (September 2017) Authors: Katelaris, CH; Maspero, JF; Jayawardena, S; Rowe, P; Maroni, J; Pirozzi, G; Amin, N; NMH, Graham; Mannent, L; Teper, A Journal: Internal medicine journal Issue: Volume 47(2017)Supplement 5 Page Start: 22 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗